+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

₹242.06 -0.96 (-0.4%)
56.17% Gain from 52W Low

04 Sep, 2026 3:51 PM (IST)

Jagsonpal Pharmaceuticals live price: ₹242.06. It opened at ₹242 vs previous close ₹243; intraday high/low: ₹243/₹239. The 50 & 200 DMA stand at ₹230.60/₹214.70.

Jagsonpal Pharmaceuticals Performance

  • Today's Low
  • ₹239
  • Today's High
  • ₹243
  • 52 Week Low
  • ₹155
  • 52 Week High
  • ₹265
  • Open Price₹242
  • Previous Close₹243
  • Volume103,221
  • 50 DMA₹230.60
  • 100 DMA₹221.60
  • 200 DMA₹214.70

Jagsonpal Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 2.84%
  • Over 3 Month + 19.84%
  • Over 6 Month + 47.1%
  • Over 1 Year -2.52%

Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!

Invest Now

Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35.1
  • PEG Ratio
  • -1.4
  • Market Cap Cr
  • 1,597
  • P/B Ratio
  • 5.5
  • Average True Range
  • 8.4
  • EPS
  • 6.9
  • Dividend Yield
  • 2.7
  • MACD Signal
  • 3.2
  • RSI
  • 58.35
  • MFI
  • 78.2

Latest Stock News Updates

Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting

Jagsonpal Pharmaceuticals Ltd - 507789 - Notice Of 47Th Annual General Meeting And Annual Report For The FY 2025-26

Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26

Jagsonpal Pharmaceuticals Ltd - 507789 - Business Responsibility and Sustainability Reporting (BRSR)

BRSR for the Financial year ended March 31, 2026

Jagsonpal Pharmaceuticals Financials

Jagsonpal Pharmaceuticals Technicals

EMA & SMA

Current Price
₹242.06
-0.96 (-0.4%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹237.00
  • 50 Day
  • ₹230.60
  • 100 Day
  • ₹221.60
  • 200 Day
  • ₹214.70

Resistance and Support

241.35 Pivot Speed
  • R3 248.30
  • R2 245.70
  • R1 243.90
  • S1 239.50
  • S2 237.00
  • S3 235.20

Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-29 Quarterly Results
2026-04-27 Audited Results & Final Dividend
2026-03-12 Buy Back of Shares
2026-01-21 Quarterly Results
2025-11-03 Quarterly Results
Date Purpose Remarks
2026-09-04 FINAL Rs.4.00 per share(200%)Final Dividend
2025-09-12 FINAL Rs.2.50 per share(125%)Final Dividend
2024-09-06 FINAL Rs.5.00 per share(100%)Final Dividend
2023-08-21 FINAL Rs.5.00 per share(100%)Dividend
2021-11-01 INTERIM Rs.4.00 per share(80%)Interim Dividend
View Jagsonpal Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2025-01-08 Split Stock split from Rs. 5/- to Rs. 2/-.
2004-07-28 Split Subdivision of equity shares from Rs. 10/- to Rs. 5/-

Jagsonpal Pharmaceuticals Shareholding Pattern

69.05%
28.04%
2.3%
0.62%

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. View More
  • NSE Symbol
  • JAGSNPHARM
  • BSE Symbol
  • 507789
  • ISIN
  • INE048B01035

Similar Stocks to Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals FAQs

Jagsonpal Pharmaceuticals share price is ₹242 As on 05 September, 2026 | 03:39

The Market Cap of Jagsonpal Pharmaceuticals is ₹1596.6 Cr As on 05 September, 2026 | 03:39

The P/E ratio of Jagsonpal Pharmaceuticals is 35.1 As on 05 September, 2026 | 03:39

The PB ratio of Jagsonpal Pharmaceuticals is 5.5 As on 05 September, 2026 | 03:39

The 52 week High & Low of Jagsonpal Pharmaceuticals is ₹264.5/₹155 respectively As on 05 September, 2026 | 03:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23